Fab'entech Revenue and Competitors

Lyon,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Fab'entech's estimated annual revenue is currently $10.5M per year.(i)
  • Fab'entech's estimated revenue per employee is $201,000

Employee Data

  • Fab'entech has 52 Employees.(i)
  • Fab'entech grew their employee count by -4% last year.

Fab'entech's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Fab'entech?

Fab'entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab')2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab'entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab'entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

keywords:N/A

N/A

Total Funding

52

Number of Employees

$10.5M

Revenue (est)

-4%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Fab'entech News

2022-04-17 - West Nile Virus Infections Medicine Market Size, Scope And ...

CEL-SCI Corp, Fab'entech SA, Hemispherx Biopharma Inc, Kineta Inc, Nanotherapeutics Inc, Plex Pharmaceuticals Inc, Theravectys SA.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$9.4M520%N/A
#2
$9.8M52N/AN/A
#3
N/A5227%N/A
#4
$11.9M536%N/A
#5
N/A5417%N/A